World Workshop on Oral Medicine VI: Clinical implications of medication-induced salivary gland dysfunction

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Volumn 120, Issue 2, 2015, Pages 185-206

  Aliko, Ardita ^a,b   Wolff, Andy ^c   Dawes, Colin ^d   Aframian, Doron ^e   Proctor, Gordon ^f   Ekström, Jörgen ^g   Narayana, Nagamani ^h   Villa, Alessandro ⁱ   Sia, Ying Wai ^j   Joshi, Revan Kumar ^k   McGowan, Richard ^l   Beier Jensen, Siri ^m   Kerr, A Ross ^l   Lynge Pedersen, Anne Marie ^m   Vissink, Arjan ⁿ  

^a University of Medicine   (Albania)

^b UNIVERSITY OF BERGEN   (Norway)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF MANITOBA   (Canada)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ BOSTON UNIVERSITY   (United States)

^j MCGILL UNIVERSITY   (Canada)

^k DAPM RV Dental College   (India)

^l NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^m UNIVERSITY OF COPENHAGEN   (Denmark)

ⁿ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; RISK FACTOR; SALIVARY GLAND DISEASE; SALIVATION;

HUMANS; RISK FACTORS; SALIVARY GLAND DISEASES; SALIVATION;

EID: 84941982759     PISSN: 22124403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oooo.2014.10.027     Document Type: Conference Paper

References (172)

1. A.V. Amerongen, and E.C.I. Veerman Saliva - the defender of the oral cavity Oral Dis 8 2002 12 22
2. A.M. Pedersen, A. Bardow, S.B. Jensen, and B. Nauntofte Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion Oral Dis 8 2002 117 129
3. A. Shafik, O. El-Sibai, A.A. Shafik, and R. Mostafa Effect of topical esophageal acidification on salivary secretion: Identification of the mechanism of action J Gastroenterol Hepatol 20 2005 1935 1939
4. J.C. Atkinson, and P.C. Fox Salivary gland dysfunction Clin Geriatr Med 8 1992 499 512
5. W.J. Loesche, J. Bromberg, M.S. Terpenning, and et al. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups J Am Geriatr Soc 43 1995 401 407
6. S.R. Porter Xerostomia: prevalence, assessment, differential diagnosis and implications for quality of life Oral Dis 16 2010 501 502
7. L.M. Sreebny Drugs, dry mouth and dentistry L.M. Sreebny, A. Vissink, Dry Mouth, the Malevolent Symptom: A Clinical Guide 2010 Wiley-Blackwell Ames, IA 89 191
8. E.A. Field, S. Fear, S.M. Higham, and et al. Age and medication are significant risk factors for xerostomia in an English population, attending general dental practice Gerodontology 18 2001 21 24
9. D. Smidt, L.A. Torpet, B. Nauntofte, K.M. Heegaard, and A.M. Pedersen Associations between labial and whole salivary flow rates, systemic diseases and medications in a sample of older people Community Dent Oral Epidemiol 38 2010 422 435
10. C. Scully Drug effects on salivary glands: dry mouth Oral Dis 9 2003 165 176
11. L. Baccaglini, M.T. Brennan, P.B. Lockhart, and L.L. Patton World Workshop on Oral Medicine IV: Process and methodology for systematic review and developing management recommendations. Reference manual for management recommendations writing committees Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 2007 S3.e1 S3.e19
12. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
13. M. Bergdahl, and J. Bergdahl Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression and stress J Dent Res 79 2000 1652 1658
14. A. Desoutter, M. Soudain-Pineau, F. Munsch, C. Mauprivez, T. Dufour, and J.L. Coeuriot Xerostomia and medication: a cross-sectional study in long-term geriatric wards J Nutr Health Aging 16 2012 575 579
15. J. Helenius-Hietala, H. Ruokonen, L. Grönroos, and et al. Self-reported oral symptoms and signs in liver transplant recipients and a control population Liver Transpl 19 2013 155 163
16. K. Ikebe, T. Nokubi, H. Sajima, and et al. Perception of dry mouth in a sample of community-dwelling older adults in Japan Spec Care Dentist 21 2001 52 59
17. T. Nederfors, R. Isaksson, H. Mörnstad, and C. Dahlöf Prevalence of perceived symptoms of dry mouth in an adult Swedish population-relation to age, sex and pharmacotherapy Community Dent Oral Epidemiol 25 1997 211 216
18. H. Pajukoski, J.H. Meurman, P. Halonen, and R. Sulkava Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92 2001 641 649
19. D. Smidt, L.A. Torpet, B. Nauntofte, K.M. Heegaard, and A.M. Pedersen Associations between oral and ocular dryness, labial and whole salivary flow rates, systemic diseases and medications in a sample of older people Community Dent Oral Epidemiol 39 2011 276 288
20. A. Bardow, B. Nyvad, and B. Nauntofte Relationships between medication intake, complaints of dry mouth, salivary flow rate and composition, and the rate of tooth demineralization in situ. Arch Oral Biol 46 2001 413 423
21. M.A. Cho, J.Y. Ko, Y.K. Kim, and H.S. Kho Salivary flow rate and clinical characteristics of patients with xerostomia according to its aetiology J Oral Rehabil 37 2010 185 193
22. I. Kaplan, L. Zuk-Paz, and A. Wolff Association between salivary flow rates, oral symptoms, and oral mucosal status Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106 2008 235 241
23. W. Murray Thomson, R. Poulton, J.M. Broadbent, and S. Al-Kubaisy Xerostomia and medications among 32-year-olds Acta Odontol Scand 64 2006 249 254
24. A. Villa, and S. Abati Risk factors and symptoms associated with xerostomia: a cross-sectional study Aust Dent J 56 2011 290 295
25. K. Youdim, and B.A. Kogan Preliminary study of the safety and efficacy of extended-release oxybutynin in children Urology 59 2002 428 432
26. K.S. Lee, H.W. Lee, M. Choo, and et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the propiverine study on overactive bladder including urgency data BJU Int 105 2010 1565 1570
27. H.Y. Leung, S.K. Yip, C. Cheon, and et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder BJU Int 90 2002 375 380
28. P.S. Patel, E.M. Gheni, and J.A. Ship Xerostomic complaints induced by an anti-sialogogue in healthy young versus older adults Spec Care Dentist 21 2001 176 181
29. C.F. Streckfus, R.C. Strahl, and S. Welsh Anti-hypertension medications: an epidemiologic factor in the prevalence of root decay among geriatric patients suffering from hypertension Clin Prev Dent 12 1990 26 29
30. M. Ryberg, C. Möller, and T. Ericson Saliva composition and caries development in asthmatic patients treated with β2-adrenoceptor agonists: a 4-year follow-up study Scand J Dent Res 99 1991 212 218
31. W.M. Thomson, G.D. Slade, and A.J. Spencer Dental caries experience and use of prescription medications among people aged 60+ in South Australia Gerodontology 12 1995 104 110
32. W.M. Thomson, A.J. Spencer, G.D. Slade, and J.M. Chalmers Is medication a risk factor for dental caries among older people? Evidence from a longitudinal study in South Australia Community Dent Oral Epidemiol 30 2002 224 232
33. V.S. Lucas Association of psychotropic drugs, prevalence of denture-related stomatitis and oral candidiasis Community Dent Oral Epidemiol 21 1993 313 316
34. S.-J. Janket, J. Jones, S. Rich, and et al. The effects of xerogenic medications on oral mucosa among the Veterans Dental Study participants Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 2007 223 230
35. L. Adler, A. Dietrich, F.W. Reimherr, and et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD Ann Clin Psychiatry 18 2006 107 113
36. C. Allgulander, I. Florea, and A.K.T. Huusom Prevention of relapse in generalized anxiety disorder by escitalopram treatment Int J Neuropsychopharmacol 9 2006 495 505
37. R.A. Appell, P. Sand, R. Dmochowski, and et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study Mayo Clin Proc 76 2001 358 363
38. R.A. Appell Clinical efficacy and safety of tolterodine in the treatment of overactive bladder Urology 0 1997 90 96
39. M. Augustin, and S. Ehrle Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients J Eur Acad Dermatol Venereol 23 2009 292 299
40. C. Blaya, A.C. Seganfredo, M. Dornelles, and et al. The efficacy of milnacipran in panic disorder: an open trial Int Clin Psychopharmacol 22 2007 153 158
41. E.S. Brown, L. Vigil, D.A. Khan, J.D. Liggin, T.J. Carmody, and A.J. Rush A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study Biol Psychiatry 58 2005 865 870
42. S. Brunton, F. Wang, B. Edwards, and et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies Drug Saf 33 2010 393 407
43. R.W. Buchanan, M.P. Ball, E. Weiner, and et al. Olanzapine treatment of residual positive and negative symptoms Am J Psychiatry 162 2005 124 129
44. L. Cardozo, T. Hall, J. Ryan, and et al. Safety and efficacy of flexible-dose fesoterodine in British patients with overactive bladder: insights into factors associated with dose escalation Int Urogynecol J 23 2012 1581 1590
45. 3-adrenoceptor agonist, in overactive bladder Eur Urol 63 2013 296 305
46. C. Collin, P. Davies, I.K. Mutiboko, S. Ratcliffe Sativex Spasticity in MS Study Group Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis Eur J Neurol 14 2007 290 296
47. R.R. Conley, C.A. Tamminga, J.J. Bartko, and et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia Am J Psychiatry 155 1998 914 920
48. L.S. Covey, M.-C. Hu, T. Winhusen, J. Weissman, I. Berlin, and E.V. Nunes OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences Drug Alcohol Depend 110 2010 156 159
49. M. Darwish, and E.T. Hellriegel Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers Clin Ther 33 2011 746 753
50. P.P. De Deyn, H. Eriksson, and H. Svensson Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomized, double-blind, parallel-group study Int J Geriatr Psychiatry 27 2012 296 304
51. K. Dickstein, C. Manhenke, T. Aarsland, J. McNay, C. Wiltse, and T. Wright The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure Int J Cardiol 75 2000 167 176
52. A.C. Diokno, R.A. Appell, P.K. Sand, and et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial Mayo Clin Proc 78 2003 687 695
53. R.R. Dmochowski, K.M. Peters, J.D. Morrow, and et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in patients with overactive bladder Urology 75 2010 62 68
54. J.F. Donohue, C. Fogarty, J. Lotvall, and et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
55. H. Drutz, R.A. Appell, D. Gleason, I. Klimberg, and S. Radomski Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynecol J Pelvic Floor Dysfunc 10 1999 293 299
56. V. Elinoff, T. Bavendam, D.B. Glasser, M. Carlsson, N. Eyland, and R. Roberts Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial Int J Clin Pract 60 2006 745 751
57. G. Fanghänel, L. Cortinas, L. Sánchez-Reyes, R. Gómez-Santos, E. Campos-Franco, and A. Berber Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension Adv Ther 20 2003 101 113
58. N.W. Flook, P. Moayyedi, J. Dent, and et al. Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial Am J Gastroenterol 108 2013 56 64
59. M. Forsting, and P. Palkowitsch Prevalence of acute adverse reactions to gadobutrol - a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials Eur J Radiol 74 2010 e186 e192
60. S. Ganesan, V. Agambaram, F. Randeree, I. Eggens, K. Huizar, and D. Meulien Study 147 Investigators. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia Curr Med Res Opin 24 2008 21 32
61. I. Gilron, J.M. Bailey, D. Tu, R.R. Holden, A.C. Jackson, and R.L. Houlden Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial Lancet 374 2009 1252 1261
62. J.L. Goldstein, J. Aisenberg, F. Lanza, and et al. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy patients aged 65 to 75 years Clin Ther 28 2006 340 351
63. C.R. Gordon, A. Gonen, Z. Nachum, I. Doweck, O. Spitzer, and A. Shupak The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance J Psychopharmacol 15 2001 167 172
64. P.K. Gross, R. Nourse, T.E. Wasser, and D. Bukenya Safety and efficacy of bupropion extended release in treating a community sample of Hispanic and African American adults with major depressive disorder: an open-label study Prim Care Companion J Clin Psychiatry 9 2007 108 112
65. K.M. Habbab, D.R. Moles, and S.R. Porter Potential oral manifestations of cardiovascular drugs Oral Dis 16 2010 769 773
66. R.M. Hackman, P.J. Havel, H.J. Schwartz, and et al. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial Int J Obes 30 2006 1545 1556
67. F.M. Haggstram, J.M. Chatkin, E. Sussenbach-Vaz, D.H. Cesari, C.F. Fam, and C.C. Fritscher A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results Pulm Pharmacol Ther 19 2006 205 209
68. J.E. Hammack, J.C. Michalak, C.L. Loprinzi, and et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy Pain 98 2002 195 203
69. M.J.P. Harnett, N. O'Rourke, M. Walsh, J.M. Carabuena, and S. Segal Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after caesarean delivery Anesth Analg 105 2007 764 769
70. S.S. Hasan, S.C. Keong, C.L. Choong, and et al. Patient-reported adverse drug reactions and drug-drug interactions: a cross-sectional study on Malaysian HIV/AIDS patients Med Princ Pract 20 2011 265 270
71. E. Hollander, L. Soorya, W. Chaplin, and et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders Am J Psychiatry 169 2012 292 299
72. K.D. Hunter, and W.S. Wilson The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva Arch Oral Biol 40 1995 983 989
73. M. Jafarinia, M.R. Mohammadi, A. Modabbernia, and et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study Hum Psychopharmacol 27 1995 411 418
74. R. Jain, A.R. Mahableshwarkar, P.L. Jacobsen, Y. Chen, and M.E. Thase A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder Int J Neuropsychopharmacol 16 1995 313 321
75. H.G. Jeong, M.S. Lee, Y.H. Ko, C. Han, and I.K. Jung Combination treatment with aripiprazole and valproic acid for acute mania: an 8-week, single-blind, randomized controlled trial Clin Neuropharm 35 2012 97 102
76. J.A. Johnston, J. Fiedler-Kelly, E.D. Glover, D.P. Sachs, T.H. Grasela, and J. DeVeaugh-Geiss Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation Nicotine Tob Res 3 2001 131 140
77. K.P. Junemann, E. Hessdorfer, I. Unamba-Oparah, and et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder Urol Int 77 2006 334 339
78. E.H. Kang, I.S. Lee, S.K. Chung, and et al. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial Psychiatry Res 169 2009 118 123
79. S.A. Kaplan, T. Schneider, J.E. Foote, Z. Guan, M. Carlsson, and J. Gong Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial BJU Int 107 2011 1432 1440
80. M.B. Keller, J.P. McCullough, D.N. Klein, and et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression N Engl J Med 342 2000 1462 1470
81. J.S. Kennedy, D. Jeste, C.J. Kaiser, and et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial Int J Geriatr Psychiatry 18 2003 1013 1020
82. C.M. Kim, Y.S. Kim, S. Sunwoo, and et al. Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care Int J Impot Res 19 2007 393 397
83. K. Kreder, C. Mayne, and U. Jonas Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder Eur Urol 41 2002 588 595
84. C.A. Kushida, A.S. Walters, P. Becker, and et al. A randomized, double-blind, placebo-controlled, crossover study of Xp13512/Gsk1838262 in the treatment of patients with primary restless legs syndrome Sleep 32 2009 159 168
85. H. Li, C. Ma, G. Wang, X. Zhu, M. Peng, and N. Gu Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: a randomized and double-blind study Curr Med Res Opin 24 2008 1 10
86. J.L. Lu, Q.L. Tang, F. De Liu, and J.H. Hui Naftopidil and tolterodine in the medical expulsive therapy for intramural ureteral stones: a prospective randomized study Urol Res 40 2012 757 762
87. R.P. Malone, M.A. Delaney, S.B. Hyman, and J.R. Cater Ziprasidone in adolescents with autism: an open-label pilot study J Child Adolesc Psychopharmacol 17 2007 779 790
88. J.G. Malone-Lee, J.B. Walsh, and M.F. Maugourd Tolterodine: a safe and effective treatment for older patients with overactive bladder J Am Geriatr Soc 49 2001 700 705
89. L.E. Mansfield, F. Hampel, J.M.C. Haeusler, and G. Georges Study of levocetirizine in seasonal allergic rhinitis Curr Med Res Opin 26 2010 1269 1275
90. N. Masumori, S. Miyamoto, T. Tsukamoto, and et al. The efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents Adv Urol 2011 2011 714978
91. L.J. Mini, S. Wang-Weigand, and J. Zhang Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty Am J Geriatr Pharmacother 5 2007 177 184
92. C.B. Nemeroff, and M.E. Thase A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients J Psychiatr Res 41 2007 351 359
93. P.A. Newhouse, K.R.R. Krishnan, P.M. Doraiswamy, E.M. Richter, E.D. Batzar, and C.M. Clary A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients J Clin Psychiatry 61 2000 559 568
94. V. Nonzee, S. Manopatanakul, and S.O. Khovidhunkit Xerostomia, hyposalivation and oral microbiota in patients using antihypertensive medications J Med Assoc Thai 95 2012 96 104
95. H. Otsuki, T. Kosaka, K. Nakamura, J. Mishima, Y. Kuwahara, and T. Tsukamoto β3-adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men Int Urol Nephrol 45 2013 53 60
96. A.J. Putland, and A. McCluskey The analgesic efficacy of tramadol versus ketorolac in daycase laparoscopic sterilisation Anaesthesia 54 1999 372 392
97. D.J. Rog, T.J. Nurmikko, T. Friede, and C.A. Young Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis Neurology 65 2005 812 819
98. A.J. Rothschild, A.R. Mahableshwarkar, P. Jacobsen, M. Yan, and D.V. Sheehan Vortioxetine (Lu Aa21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States Eur Neuropsychopharmacol 22 2012 858 866
99. D. Rudy, K. Cline, R. Harris, K. Goldberg, and R. Dmochowski Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment BJU Int 97 2006 540 546
100. J.A. Sánchez-Lacay, R. Lewis-Fernández, D. Goetz, and et al. Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues Depress Anxiety 13 2001 118 124
101. P.K. Sand, E.S. Rovner, J.H. Watanabe, and M.G. Oefelein Once-daily trospium chloride 60 mg extended release in patients with overactive bladder syndrome who use multiple concomitant medications. Post hoc analysis of pooled data from two randomized, placebo-controlled trials Drugs Aging 28 2011 151 160
102. L. Schmitt, B. Tonnoir, and C. Arbus Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder Neuropsychobiology 54 2007 201 207
103. E.C. Settle, S.M. Stahl, S.R. Batey, J.A. Johnston, and J.A. Ascher Safety profile of sustained-release bupropion in depression: results of three clinical trials Clin Ther 21 1999 454 463
104. S.E. Shoaf, Z. Wang, P. Bricmont, and S. Mallikaarjun Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy patients J Clin Pharmacol 47 2007 1498 1507
105. S. Shoptaw, A. Huber, J. Peck, and et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence Drug Alcohol Depend 85 2006 12 18
106. J.A. Stapleton, L. Watson, L.I. Spirling, and et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness Addiction 103 2008 146 154
107. D.R. Staskin, M.T. Rosenberg, P.K. Sand, N.R. Zinner, and R.R. Dmochowski Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials Int J Clin Pract 63 2009 1715 1723
108. M. Takei, Y. Homma Japanese Tolterodine Study Group Long-term safety, tolerability and efficacy of extended release tolterodine in the treatment of overactive bladder in Japanese patients Int J Urol 12 2005 456 464
109. J.M. Tamayo, G. Mazzotti, M. Tohen, and et al. Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol J Clin Psychopharmacol 27 2007 126 134
110. M. Tohen, T.M. Sanger, S.L. McElroy, and et al. Olanzapine versus placebo in the treatment of acute mania Am J Psychiatry 156 1999 702 709
111. M. Versiani, G. Cassano, G. Perugi, and et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder J Clin Psychiatry 63 2002 31 37
112. E. Vieta, J. Mullen, M. Brecher, B. Paulsson, and M. Jones Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomized, placebo-controlled studies Curr Med Res Opin 21 2005 923 934
113. T.E. Wilens, T. Klint, L. Adler, and et al. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD Behav Brain Funct 4 2008 24 33
114. P. Winner, D. Lewis, W.H. Visser, K. Jiang, S. Ahrens, J.K. Evans Rizatriptan Adolescent Study Group Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study Headache 42 2002 49 55
115. M. Marttila, J. Jaaskelainen, R. Jarvi, and et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression Eur Neuropsychopharmacol 5 1995 441 446
116. D. Feltner, H.-U. Wittchen, R. Kavoussi, J. Brock, F. Baldinetti, and A.C. Pande Long-term efficacy of pregabalin in generalized anxiety disorder Int Clin Psychopharmacol 23 2008 18 28
117. K. Kamijima, T. Burt, G. Cohen, I. Arano, and T. Hamasaki A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan Int Clin Psychopharmacol 21 2006 1 9
118. T. Wigal, M. Brams, M. Gasior, J. Gao, L. Squires, J. Giblin 316 Study Group Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design Behav Brain Funct 6 2010 34 47
119. L.M. Arnold, B. Emir, T.K. Murphy, and et al. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia Clin Ther 34 2012 1092 1102
120. N.R. Zinner, R.R. Dmochowski, D.R. Staskin, P.F. Siami, P.K. Sand, and M.G. Oefelein Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms Neurourol Urodynam 30 2011 1214 1219
121. M. Mavissakalian, J. Perel, and S. Guo Specific side effects of long-term imipramine management of panic disorder J Clin Psychopharmacol 22 2002 155 161
122. M. Bauer, N. El-Khalili, C. Datto, J. Szamosi, and H. Eriksson A pooled analysis of two randomized, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder J Affect Disord 127 2010 19 30
123. G.A. Bray, G.L. Blackburn, J.M. Ferguson, and et al. Sibutramine produces dose-related weight loss Obes Res 7 1999 189 198
124. W.A. Hening, R.P. Allen, W.G. Ondo, and et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States Mov Disord 25 2010 1675 1683
125. J.M. Kane, R. Yang, and J.M. Youakim Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study Schizophrenia Res 135 2012 116 122
126. H.A.M. Kerstjens, B. Disse, W. Schroder-Babo, and et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial J Allergy Clin Immunol 128 2011 308 314
127. S. Landy, C.A. Altman, and F. Xie Time to recovery in patients with acute painful musculoskeletal conditions treated with extended-release or immediate-release cyclobenzaprine Adv Ther 28 2011 295 303
128. S.J. Cotler, C.F. Wartelle, A.M. Larson, D.R. Gretch, D.M. Jensen, and R.L. Carithers Jr. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C J Viral Hepat 7 2000 211 217
129. J.C. Gallagher, R.A. Strzinek, R.F.J. Cheng, M.K. Ausmanas, D. Astl, and P. Seljan The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause J Womens Health 21 2012 188 198
130. J.P. Houston, M. Tohen, E.K. Degenhardt, H.H. Jamal, L.L. Liu, and T.A. Ketter Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study J Clin Psychiatry 70 2009 1540 1547
131. N.C. Vulink, D. Denys, S.B. Fluitman, J.C. Meinardi, and H.G. Westenberg Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients J Clin Psychiatry 70 2009 1001 1008
132. S. Akhondzadeh, R. Ghayyoumi, F. Rezaei, and et al. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial Psychopharmacology 213 2011 809 815
133. J.O. Brooks, J.F. Goldberg, T.A. Ketter, and et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the systematic treatment enhancement program for bipolar disorder J Clin Psychiatry 72 2011 240 247
134. S.D. Chung, H.C. Chang, B. Chiu, C.H. Liao, and H.C. Kuo The efficacy of additive tolterodine extended release for 1 year in older men with storage symptoms and clinical benign prostatic hyperplasia Neurourol Urodyn 30 2011 568 571
135. R.J. Mier, S.J. Bachrach, R.C. Lakin, T. Barker, J. Childs, and M. Moran Treatment of sialorrhea with glycopyrrolate. A double-blind dose-ranging study Arch Pediatr Adolesc Med 154 2000 1214 1218
136. S.A. Kaplan, K. Walmsley, and E.A. Te Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia J Urol 174 2005 2273 2276
137. E. Ceskova, J. Suchopar, and Z. Priborska Safety of amisulpride in combination with antidepressants under common clinical practice conditions Int J Psychiatry Clin Pract 15 2011 157 161
138. L. Manchikanti, K.N. Manchikanti, V. Pampati, and K.A. Cash Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain Pain Physician 12 2009 259 267
139. D. Barton, B. La Vasseur, C. Loprinzi, P. Novotny, M.B. Wilwerding, and J. Sloan Venlafaxine for the control of hot flashes: results of a longitudinal continuation study Oncol Nurs Forum 29 2002 33 40
140. T.L. Griebling, S.R. Kraus, H.E. Richter, D.B. Glasser, and M. Carlsson Tolterodine extended release is well tolerated in older subjects Int J Clin Pract 63 2009 1198 1204
141. W. Oertel, P. LeWitt, N. Giladi, L. Ghys, F. Grieger, and B. Boroojerdi Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability Parkinsonism Relat Disord 19 2013 37 42
142. C. Barbui, M. Nosè, J. Bindman, and et al. Sex differences in the subjective tolerability of antipsychotic drugs J Clin Psychopharmacol 25 2005 521 526
143. A. Wolff, P.C. Fox, J.A. Ship, J.C. Atkinson, A.A. Macynski, and B.J. Baum Oral mucosal status and major salivary gland function Oral Surg Oral Med Oral Pathol Oral Radiol Endod 70 1990 49 54
144. P.C. Fox, K.A. Busch, and B.J. Baum Subjective reports of xerostomia and objective measures of salivary gland performance J Am Dent Assoc 115 1987 581 584
145. J.A. Ship, P.C. Fox, and B.J. Baum How much saliva is enough? "Normal" function defined J Am Dent Assoc 122 1991 63 69
146. E.M. Hay, E. Thomas, B. Pal, A. Hajeer, H. Chambers, and A.J. Silman Weak association between subjective symptoms and objective testing for dry eyes and mouth: result from a population based study Ann Rheum Dis 57 1998 20 24
147. T. Nederfors, V. Henricsson, C. Dahlöf, and T. Axéll Oral mucosal friction and subjective perception of dry mouth in relation to salivary secretion Scand J Dent Res 101 1993 44 48
148. T. Nederfors, and C. Dahlöf Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human whole saliva flow rate and composition Arch Oral Biol 37 1992 579 584
149. T. Nederfors, B. Nauntofte, and S. Twetman Effects of furosemide and bendroflumethiazide on saliva flow rate and composition Arch Oral Biol 49 2004 507 513
150. R.G. Smith, and A.P. Burtner Oral side-effects of the most frequently prescribed drugs Spec Care Dentist 14 1994 96 102
151. D.R. Abernethy, and D.A. Flockhart Molecular basis of cardiovascular drug metabolism-implications for predicting clinically important drug interactions Circulation 101 2000 1749 1753
152. C.R. Chapple Muscarinic receptor antagonists in the treatment of overactive bladder Urology 55 2000 33 46
153. M. Navazesh, V.J. Brightman, and J.M. Pogoda Relationship of medical status, medications, and salivary flow rates in adults of different ages Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81 1996 172 176
154. M.M. Koller, K.R. Purushotham, N. Maeda, P.J. Scarpace, and M.G. Humphreys-Beher Desipramine induced changes in salivary proteins, cultivable oral microbiota and gingival health in aging female NIA Fischer 344 rats Life Sci 68 2000 445 455
155. H. Flink, M. Bergdahl, A. Tegelberg, A. Rosenblad, and F. Lagerlöf Prevalence of hyposalivation in relation to general health, body mass index and remaining teeth in different age groups of adults Community Dent Oral Epidemiol 36 2008 523 531
156. S.S. Anttila, M.L.E. Knuuttila, and T.K. Sakki Depressive symptoms as an underlying factor of the sensation of dry mouth Psychosom Med 60 1998 215 218
157. A. Wolff, L. Zuk-Paz, and I. Kaplan Major salivary gland output differs between users and non-users of specific medication categories Gerodontology 25 2008 210 216
158. L.A. Tabak, M.J. Levine, I.D. Mandel, and S.A. Ellison Role of salivary mucins in the protection of the oral cavity J Oral Pathol 11 1982 1 17
159. M. Bergdahl, and J. Bergdahl Perceived taste disturbance in adults: prevalence and association with oral and psychological factors and medication Clin Oral Invest 6 2002 145 149
160. R.S. Brown, A.M. Krakow, T. Douglas, and S.K. Choksi "Scalded mouth syndrome" caused by angiotensin converting enzyme inhibitors: two case reports Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83 1997 665 667
161. D. Triantos, and P. Kanakis Stomatodynia (burning mouth) as a complication of enalapril therapy Oral Dis 10 2004 244 245
162. B.J. Cowart Taste dysfunction: a practical guide for oral medicine Oral Dis 17 2011 2 6
163. T.E. Daniels, and P.C. Fox Salivary and oral components of Sjögren's syndrome Rheum Dis Clin North Am 18 1992 571 589
164. T. Aoba Solubility properties of human tooth mineral and pathogenesis of dental caries Oral Dis 10 2004 249 257
165. G.H. Gilbert, M.W. Heft, and R.P. Duncan Mouth dryness as reported by older Floridians Community Dent Oral Epidemiol 21 1993 390 397
166. M.I. MacEntee, D.C. Clark, and N. Glick Predictors of caries in old age Gerodontology 10 1993 90 97
167. D. Beighton, P.H. Hellyer, E.J.R. Lynch, and M.R. Heath Salivary levels of mutans streptococci, lactobacilli, yeasts, and root caries prevalence in non-institutionalized elderly dental patients Community Dent Oral Epidemiol 19 1991 302 307
168. K.C. Leung, A.S. McMillan, B.P.K. Cheung, and W.K. Leung Sjögren's syndrome sufferers have increased oral yeast levels despite regular dental care Oral Dis 14 2008 163 173
169. B. Kuru, M.J. McCullough, S. Yilmaz, and S.R. Porter Clinical and microbiologic studies of periodontal disease in Sjögren's syndrome patients J Clin Periodontol 29 2002 92 102
170. L. Jorkjend, A. Johansson, A.K. Johansson, and A. Bergenholtz Periodontitis, caries and salivary factors in Sjögren's syndrome patients compared to sex- and age-matched controls J Oral Rehab 30 2003 369 378
171. K.G. Brooks, and D.F. Thompson A review and assessment of drug-induced parotitis Ann Pharmacother 46 2012 1688 1699
172. P. Diz Dios, and C. Scully Adverse effects of antiretroviral therapy: focus on orofacial effects Expert Opin Drug Saf 1 2002 307 317